Innovation Partners
A massive thank you to the companies and organizations that brings together our community of innovators shaping the future of the clinical trial industry.
We’re already working with potential Partners for our next event in 2026. Start a conversation with our team to learn how you can invest and directly support these critical conversations.
Our Official 2026 Partners
(More partners to be announced soon)
Medidata, a Dassault Systèmes brand, is a global leader in clinical trial solutions, powering over 38,000 trials and serving more than 12 million patients worldwide.
With industry-leading expertise, analytics-driven insights, and one of the largest clinical trial data sets, Medidata’s end-to-end platform is trusted by one million users across 2,300 organizations. Their mission: to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster.
YPrime streamlines the clinical trial journey with a configurable platform designed for speed, quality, and certainty. With 50% faster IRT startup times, up to 30% faster eCOA launch times, and quality standards 50% above the industry average. YPrime helps solve for certainty.
Florence Healthcare is a leading provider of the Site Enablement Platform, committed to accelerating cures by better connecting sponsors, CROs, and research sites.
The company's integrated platform streamlines the clinical trial process, enabling seamless collaboration and more efficient management of clinical research workflows. Florence Healthcare is dedicated to fostering innovation and improving patient outcomes worldwide with over 12,000 connected research sites on its platform in 45 countries, facilitating more than 6.5 million research workflows every month.
Purpose-built by healthcare for healthcare, Evinova empowers life science leaders to accelerate better health outcomes with digital and AI-native solutions that optimize clinical development from end to end.
Clinigen is a global pharmaceutical services company trusted by over 1,000 pharma and biotech partners. With more than 35 years of experience, we accelerate access to critical medicines at every stage of the product lifecycle. As pathfinders, our team of over 1,100 specialists expertly navigate the complexities of clinical trial supply, early access programs, regulatory services, and long-term commercialization through both licensed and unlicensed pathways. Operating across five continents, we deliver innovative solutions to over 130 countries each year. Whatever the challenge, we find a way.
The Association of Multisite Research Corporations (AMRC)represents multisite clinical research corporations (MCRCs) and advocates for the value these organizations bring to sponsors, CROs, policy makers and patients. At ING2026, AMRC will be partnering on a Dive Team focused on how to define quality at the institutional and site levels.
Clinical Enrollment is a success-based patient recruitment company that takes full ownership of clinical trial enrollment outcomes — managing everything from patient identification through screening and site follow-through, and only getting paid on success.
Clinical Enrollment closes enrollment an average of nearly two months faster than industry norms and delivers a 4.4x increase in recruitment speed, while achieving a 32% under-represented patient population rate. With deep expertise across therapeutic areas including oncology, CNS, rare disease, and dermatology, Clinical Enrollment is redefining what accountability in patient recruitment looks like.
ACRO advocates as the collective voice of innovative clinical research and technology organizations to regulators and policymakers, educating stakeholders and advocating for policies that foster efficient, effective and safe conduct of clinical research.
Note to File is a podcast for the clinical research community - featuring interviews, candid commentary, and general nonsense from Brad Hightower and Denali Rose.
The podcast was born with the hope of providing a platform for research professionals to share their stories, tackle real challenges, and offer some practical advice for the clinical research community - assuming we manage to stay on track.
The Clinical Research Site Collective (CRSC) was built around one belief: that sites are central to clinical research, and everyone benefits when the industry reflects that. As a web-based community, CRSC brings together sites, sponsors, CROs, service partners, and patient advocates to tackle the operational and financial realities that determine whether trials succeed or stall. Members gain visibility and connections across the clinical research ecosystem, access to free resources, webinars, and both in-person and virtual networking opportunities.
CRSC believes the future of human-centric clinical research runs through sites that are well-supported, fairly resourced, and genuinely included in the conversations that affect them. CRSC exists to make that happen.
KPS Life is a stand-alone functional service provider (FSP) built to function as a true partner to sponsors.
They embed highly vetted experts into sponsor teams for the duration of clinical trials—delivering continuity,
stability, and measurable outcomes. With a high-touch, consultative approach that reduces friction and eases
pressure, we help accelerate the development of life-changing therapies worldwide.
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. The company leverages the potential of Artificial Intelligence, using Advanced Statistics and Machine Learning, to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R3), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management, and to drive a holistic Risk-Based strategy in all trials.
Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls, and solution implementation, CluePoints provides everything needed to adhere to global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs, and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
